(DSCO) FDA DECISION 6 MARCH=5 BAGGER (Mcap 53 M) !!!
TIME TO LOAD UP THE VERY CHEAP SHARES OF THIS ALMOST UNKNOW LOW FLOAT MONSTER .MARKET CAP OF 53 M IS A BIG JOKE .GLTA
Surfaxin has $ 500 M market potential once approved it will push DSCO into Double Digits easily .
DSCO is significantly at current levels .FDA runup could start any time now which will drive this LOW FLOAT MONSTER to 4-5 Dollars .
GREAT BUYING OPPORTUNITY HERE ....
Discovery Labs (DSCO)
Market Cap : $ 53 M Cash : $ 15.4 M Price : 2.18
Shares Out : 24 .5 M
Discovery Laboratories (DSCO) – Decision Date: March 6, 2012
Drug: Surfaxin – Treatment: prevention of respiratory distress syndrome in premature infants.
Discovery Labs also has a few drugs in its pipeline. Aerosurf is in Phase 2 for the treatment of moderate respiratory distress syndrome. Liquid KL4 Surfactant is in Phase 2 to treat a wide range of respiratory diseases. Aerosolized KL4 Surfactant is in early development to treat acute lung injury and bronchiectasis. The same drug is in Phase 2 for treating cystic fibrosis.